Skip to search formSkip to main contentSkip to account menu

AXL Inhibitor BGB324

Known as: BGB324 
An orally available and selective inhibitor of the AXL receptor tyrosine kinase (UFO), with potential antineoplastic activity. Upon administration… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
7043 Background: The RTK AXL represents a therapeutic target promoting AML cell proliferation and survival by pleiotropic… 
Review
2018
Review
2018
Tyrosine kinase receptor 3 (Tyro3), Axl, and Mer constitute the TAM family of receptor tyrosine kinases. These receptor tyrosine… 
2018
2018
TPS43Background: Activation of the receptor tyrosine kinase AXL has a profound suppressive effect on the innate immune system… 
2018
2018
9548Background: Upregulation of the receptor tyrosine kinase Axl has been linked with both a reduced response to PD-1 blockade… 
2018
2018
3078Background: Bemcentinib (BGB324) is a first-in-class, oral, potent and highly selective inhibitor of the AXL tyrosine kinase… 
2017
2017
The AXL receptor tyrosine kinase is associated with poor overall survival in a wide spectrum of cancers including lung and breast… 
2016
2016
Axl is a receptor tyrosine kinase that has been shown to have a strong oncogenic potential in many cancer types. Overexpression… 
2015
2015
Novel treatment options in acute myeloid leukemia (AML) are urgently needed; treatment has not changed significantly over the… 
2014
2014
BCR-ABL1 inhibitors have revolutionized the treatment of CML patients. However several drawbacks remain, including clinical…